Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.97 USD | +1.56% | -0.24% | -45.87% |
Apr. 23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
Apr. 22 | Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.87% | 2.76B | |
+2.48% | 42.75B | |
+47.92% | 41.61B | |
+11.98% | 41.34B | |
-12.36% | 26.59B | |
+8.21% | 25.49B | |
-23.00% | 18.12B | |
+30.83% | 12.24B | |
-1.91% | 11.76B | |
+7.95% | 11B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- ACADIA Pharma Acquires Ex-North America Rights to Trofinetide, Global Rights to NNZ-2591; Shares Surge Premarket